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Abstract 
The atypical antipsychotic Abilify is the second most popular treatment for schizophrenia and 
other related disorders. Its popularity and wide use is due to its unique pharmacological profile, 
working differently at dopamine and serotonin receptors compared to other antipsychotics. 
Schizophrenia is an infamous mental dysfunction involving cognitive impairment, positive 
symptoms, and negative symptoms. The current study investigated Abilify’s effect in a dose-
dependent manner on memory, coordination and stereotypic movement. The sample consisted of 
15 male and 15 female CD-1 mice. Memory was tested in a cognitive maze, the Rota-Rod series 
8 model measured coordination, and the Coulbourn Tru-Scan Activity Box recorded stereotypic 
movements. Abilify did not significantly affect memory, it inhibited coordination at all doses for 
female mice and at the highest dose for male mice, and it induced stereotypic movements at the 
lowest dose and inhibited such movements at the highest dose for male and female mice. 
Keywords: Abilify, aripiprazole, antipsychotic, schizophrenia, dopamine, serotonin, memory, 
cognitive maze, coordination, Rota-Rod, stereotypy, Tru-Scan, CD-1 mice 
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The Effect of Abilify on Memory, Coordination, and Stereotypy in CD-1 Mice 
 Abilify is the second most popular pharmacological treatment for schizophrenia and 
psychosis-related disorders, yet there is scarce scientific literature on patients’ premorbid history 
prior to being placed on this highly influential drug. Additionally, there is very little literature 
pertaining to long-term use of Abilify in the clinical population; however, there is an abundance 
of novel information on the behavioral, molecular, and social aspects of schizophrenia. This 
thesis will explain the psychopathology of schizophrenia and the relevance of Abilify as a 
psychotropic medication and explain many of the side effects of various doses of this 
medication, as well as investigate its effects on memory, coordination, and stereotypic 
movement. 
One of the most infamous and well-known mental dysfunctions, schizophrenia is both as 
fascinating a disorder as it is misunderstood. Schizophrenia involves three key dimensions: 
cognitive impairment, positive symptoms, and negative symptoms (Rajagopal, Massey, Huang, 
Oyamada & Meltzer, 2014). Positive symptoms include hallucinations (false perceptions), 
delusions (false beliefs), and deranged thoughts and behaviors, while negative symptoms include 
loss of motivation, affective flattening, restricted emotional experience, reduced hedonic 
capacity, and disorganized speech (saying things that do not make sense) (Topolov & Getova, 
2016). It is not unusual for schizophrenic patients to suffer from abnormal perceptions 
(eyetracking problems, slight movement disturbances), strange inferential judgments that lead to 
extraordinary beliefs and delusions, restricted emotions, and widespread cognitive problems 
(Topolov & Getova, 2016). 
Schizophrenia is a devastating disorder for both patients and families and the second 
leading cause of disease burden. The three phases of most schizophrenic patients include the 
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prodromal phase, the active phase, and the residual phase. The prodromal phase is more 
important to this thesis since it includes peculiar behaviors, such as pacing, movement 
disturbances and restlessness. Although there are 3 key symptoms, no single symptom or specific 
set of symptoms is characteristic of all schizophrenic patients. Since there are many different 
clinical manifestations and levels of severity, The Diagnostic and Statistical Manual of Mental 
Disorders now lists Schizophrenia under Spectrum Psychotic Disorders. This heading now 
includes schizophrenia, schizoaffective disorder, delusional disorder, brief psychotic disorder, 
and psychotic mania, all of which might be alleviated or attenuated by the drug Abilify. 
Although there is a commonality involving a break in reality with all of these disorders, the three 
dimensions are mostly uncorrelated and consequently respond differently to antipsychotic 
treatment (Rajagopal et al., 2014). Specifically, cognitive impairment prevents patients from 
learning and memorizing the skills that are necessary for social relationships, accounting for 
more poor functional outcomes such as occupational functioning, social attainment, and 
independent living, than the other two dimensions, and in schizophrenic patients this might 
become visible before other neurological impairments, affecting working memory, attention, and 
learning (Topolov & Getova, 2016). Typically, cognitive impairments present first, developing 
completely before the onset of psychotic episodes in schizophrenic patients, but not in 
schizoaffective, schizophreniform, or manic psychotic patients (Topolov & Getova, 2016). 
Therefore, it would be beneficial to understand the effects of Abilify on memory prior to 
administration as well as future long-term effects on cognition. 
The psychotic episodes involve breaks in reality and includes disconnected ideas (using 
words in peculiar ways, loose associations, otherwise known as derailment (i.e., switching topics 
too abruptly), and perseveration (e.g., persistently repeating the same word or phrase over and 
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over). This can even develop into what is now known as thoughtblocking, where the patient’s 
train of thought is interrupted before an idea has been completed. Disorganization is another 
commonly seen bizarre behavior which may include a catatonic-like psychosis, which involves 
immobility and marked muscular rigidity, or wild excitement and overactivity. This altered state 
of responsiveness is of primary importance to this thesis, since most antipsychotic medications 
will further sedate or suppress movement. 
While systematic tests for schizophrenia were developed by the 1940s, most of what is 
known regarding cognitive impairment in psychotic related illnesses came from targeted research 
that began in the 1980s (Topolov & Getova, 2016). Schizophrenic patients have been found to 
perform worse than control patients in all twelve neurocognitive domains: general intellectual 
ability, verbal memory, nonverbal memory, recognition, executive functions, motor skills, 
working memory, language, attention, and processing speed (Topolov & Getova, 2016). In 
particular, schizophrenic patients’ ability to work fulltime is impacted by cognitive functioning, 
even prior to drug administration. Readministration of IQ tests to individuals who developed 
schizophrenia showed little change, implying that most of the intellectual decline occurred prior 
to the onset of the first psychosis (Topolov & Getova, 2016). For schizophrenics, the severity of 
the cognitive impairment in their first-episode is equivalent to the cognitive impairment in 
individuals with chronically established schizophrenia, highlighting neurocognitive deficits as 
one of the more stable traits of schizophrenia (Topolov & Getova, 2016). Moreover, genetic 
relatives of schizophrenic patients have shown attenuated cognitive impairment, meaning that 
neurocognitive domains may be genetic markers for schizophrenia (Topolov & Getova, 2016). 
 The success of various pharmacological therapies in psychotic patients has led to the 
proposal of 3 models: the dopamine hypothesis, the glutamate hypothesis, and the serotonin 
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hypothesis. Each model attempts to explain both the neuroreceptor targets for antipsychotics and 
how various neuroreceptors influence specific symptoms and side effects (Topolov & Getova, 
2016). Among the models, the dopamine hypothesis is the most studied. It states that 
schizophrenia is due to an abundance of dopamine in the brain. More precesily, it suggests that 
hyperactivity of the mesolimbic dopaminergic pathway mediates symptoms of psychosis, while 
the negative and cognitive symptoms are mediated by separate mesocorted hypoactive 
dopaminergic pathways (Topolov & Getova, 2016). However, we now have greater technology 
showing us that this hypothesis does not tell the whole story. There are other interactions as 
previously stated with GABA and glutamate, but also with serotonin pathways (explaining most 
of the negative symptoms). COMT (located on chromosome 22) has also been looked at. This is 
a specific gene that is involved in breaking down the neurotransmitter dopamine, which may 
contribute to the movement disorders that are linked to the dysfunction as well as the 
medications to the dysfunction. Extrapyramidal symptoms (EPS) are motor side effects due to 
long standing treatments with antipsychotics; however, literature is now showing that some of 
the tremors, restlessness, and muscular rigidity are due to the imbalance of dopamine in the brain 
and not due to medications alone. Although the glutamate hypothesis states that schizophrenia is 
the result of hypo-activity on NMDA receptors, these receptors rarely modulate memory or 
movement (Leite, Guimaraes, & Moreira, 2008). However, the glutamate and serotonin 
hypothesis are less important with this thesis since Abilify primarily affects the dopamine 
system, involved in active symptoms, cognition, and movement. 
While patients with schizophrenia demonstrate deficits across many cognitive domains, 
the underlying cognitive and neural mechanisms of the disorder are unclear. For instance, the 
striatal dopamine system is involved in signaling prediction errors and integrating them over 
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trials, while the prefrontal cortex is involved in using working memory to test hypotheses and 
represent values of prospective outcomes to guide choice (Collins, Brown, Gold, Waltz & Frank, 
2014). The contributions of two separable cognitive processes, working memory (WM) and 
reinforcement learning (RL), are confounded by most learning paradigms, leading Collins et al. 
to develop a model to separate WM from RL. While patients with schizophrenia do show failure 
in RL, Collins et al. found that learning impairment in schizophrenic patients was due to deficits 
in WM rather than deficits in RL (2014). More precisely, they found that patients with 
schizophrenia had reduced WM capacity and faster WM decay, while RL rates were normal. 
This suggests that the inability of patients with schizophrenia to learn from outcomes stems from 
WM deficits rather than RL deficits. WM contributes to other aspects of cognition, including 
fluid reasoning and language comprehension, meaning that WM impairments could contribute to 
many of the cognitive deficits seen in schizophrenia, and thus would be detrimental to put them 
on a medication that might increase their memory loss. While they hypothesized that negative 
symptom severity was related to WM parameters, no association was found, perhaps because the 
task they used more closely related to WM processes involving the lateral prefrontal cortex, 
while negative symptoms are hypothesized to be attributed to the limbic portions of the 
prefrontal cortex, such as the orbitofrontal cortex (Collins et al., 2014). 
Neuroanatomical studies of the dopamine system are widely published; however, there 
are very little, if no studies, identifying the effect on neural communication, both pre- and post-
medication. Interdependence of firing rates in dorsolateral prefrontal cortex and parietal cortex is 
vital for WM performance (Deserno, Sterzer, Wustenberg, Heinz, & Schlagenhauf, 2012). The 
dysconnectivity hypothesis of schizophrenia focuses on abnormal synaptic plasticity. WM-
dependent modulation of effective connectivity from dorsal-lateral prefrontal cortex (dlPFC) to 
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parietal cortex was shows to be reduced in schizophrenic patients, showing that this 
dysconnectivity could be a specific mechanism underlying cognitive deficits seen in 
schizophrenia (Deserno et al., 2012). 
Typical antipsychotics, such as Thorazine and mellaril, can reduce the activity of 
hyperactive dopaminergic pathways by inhibiting dopamine transmission, thus reducing positive 
symptoms that are related to hallucinations and delusions (Topolov & Getova, 2016). More 
precisely, typical antipsychotics work as full antagonists at dopamine D2 receptors (Topolov & 
Getova, 2016). However, the dopamine inhibition causes unwanted side motor effects, but less 
dry mouth and memory disturbances. However, some psychotropic medications (Thioridazine, 
Haldol, and other piperadines) diminish levels of dopamine in pathways where dopamine excess 
was not a problem, such as the mesocortical, nigrostriatal, and tuberoinfundibular pathways, and 
thus induce extrapyramidal side effects (EPS) and possibly cause cognitive impairment (Topolov 
& Getova, 2016). Negative symptoms and cognitive symptoms often worsen on long-term 
psychotropic medications, since these behaviors are not mediated through typical dopamine 
receptor subtypes, but rather incorporate other systems, such as the serotonin and norepinephrine 
systems (Topolov & Getova, 2016). 
Consequently, D2 receptor antagonists are known to induce catalepsy and cause increased 
dopamine metabolism in the striatum, where their effects contribute to extrapyramidal motor side 
effects (EPMS), and in the limbic system, where their effects contribute to antipsychotic activity 
(Kirschbaum, Hiemke, & Schmitt, 2009). To provide an example of EPMS, D2 receptors have 
been shown to play a role in central components of locomotion, such as time spent in motion, 
horizontal distance traveled, and initiating movement, meaning that D2 receptor antagonists 
could inhibit locomotion (Kirschbaum et al., 2009). As demonstrated by Sanberg’s 1980 study, a 
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typical antipsychotic such as haloperidol would induce catalepsy by blockade of postsynaptic 
striatal dopamine D2 receptors (qtd. in Kirschbaum et al., 2009).  Atypical antipsychotics, such 
as clozapine, Risperdal, and Abilify, work on serotonin receptors in addition to dopamine 
receptors, and are known for inducing less EPS than typical antipsychotics (Topolov & Getova, 
2016). Additionally, atypical antipsychotics do not increase prolactin secretion and may improve 
cognitive impairment (Topolov & Getova, 2016). It has been shown that the preferable EPS 
effects are attributed to serotonin 5-HT2A,C receptor antagonism and/or 5-HT1A partial agonism, 
while the cognitive enhancement is attributed to 5-HT6 and 5-HT7 receptor antagonism (Topolov 
& Getova, 2016). Moreover, the pathophysiologic mechanism of schizophrenia is thought to be 
based on too much dopamine activity in some regions and too little dopamine activity in other 
regions, which has led to research focusing on developing D2 partial agonists. These could work 
as antagonists in areas with too much dopamine activity, and work as agonists in areas with low 
dopamine activity (Topolov & Getova, 2016). Thus, D2 partial agonists could reduce positive 
symptoms while not inducing EPS or elevated prolactin levels. 
 Aripiprazole (brand name Abilify) is a psychotropic drug commonly used to treat many 
forms of psychosis. It is available as tablets, orally disintegrated tablets, oral solution, and 
injection (Topolov & Getova, 2016). Its chemical formula is 7-[4-[4-(2,3-dichlorophenyl)-1-
piperazinyl]butoxy]-3,4-dihydrocarbostyril, while the empirical formula is C23H27Cl2N3O2, and 
its molecular weight is 448.39 (Topolov & Getova, 2016). After oral administration, peak plasma 
concentrations occur after 5 to 7 hours, and the absolute oral bioavailability is 87% (Topolov & 
Getova, 2016). When administered intramuscularly, the peak time is between 1 and 3 hours and 
the absolute bioavailability is 100% (Topolov & Getova, 2016). There are 3 primary 
biotransformation pathways that metabolize aripiprazole: dehydrogenation, hydroxylation, and 
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N-dealkylation (Topolov & Getova, 2016). The elimination half-life is considered to fall within 
75 hours to 146 hours. The active metabolite, dehydro-aripiprazole, is present for an additional 
146 hours. The cytochrome P 450 enzymes CYP3A4 and CYP2D6 are responsible for 
aripiprazole metabolism. 
 Despite being an atypical antipsychotic, aripiprazole’s mechanism of action differs from 
other atypical antipsychotics such as clozapine, olanzapine, and risperidone. Where other 
antipsychotics act as antagonists at D2 receptors, aripiprazole acts as a partial agonist at D2 
receptors and at 5-HT1A receptors (Topolov & Getova, 2016). Aripiprazole’s profile leads to 
antagonistic activity in areas with dopaminergic hyperactivity and agonist activity in areas with 
dopaminergic hypoactivity, decreasing the risk of EPS and some catalepsy compared to some 
older antipsychotics and other new atypical antipsychotics (Kirschbaum et al., 2009). Two 
animal models for predicting EPS in humans are inducing catalepsy in rodents that reflects the 
substantial decrease in dopamine signaling at postsynaptic striatal D2 receptors and the Rota-Rod 
test, which tests coordinated motor skills. In their 2009 study, Kirschbaum et al. investigated the 
effects of aripiprazole and other antipsychotics on motor impairment using the catalepsy and 
Rota-Rod tests. Three doses of aripiprazole were administered: 1mg/kg, which showed no motor 
impairment, and 5mg/kg and 10mg/kg, which caused significant motor impairments and also 
induced catalepsy (Kirschbaum et al., 2009). Aripiprazole induced less motor impairment than 
haloperidol or risperidone, as these drugs caused impairments even at low doses (Kirschbaum et 
al., 2009). Also, 5-HT1A receptor activation increases dopamine release in a regionally selective 
manner in the prefrontal cortex, suggesting alleviation of the proposed deficiency in 
dopaminergic neurotransmission in this brain region in schizophrenics (Bardin, Kleven, Barret-
Grevoz, Depoortere, & Newman-Tancredi, 2005). Activation of this receptor has also been 
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shown to improve negative symptoms as well as cognitive symptoms (Bardin et al., 2005). Like 
other antipsychotics, aripiprazole works as an antagonist at 5-HT2A receptors and the 5-HT7 
receptor, and it also works as a partial agonist at the 5-HT2C receptor (Topolov & Getova, 2016). 
Aripiprazole has been shown to enhance short-term memory and long-term memory on the 
inhibitory avoidance task (Nascimento et al., 2011) 
 Aripiprazole dampens the action of dopamine and serotonin in the brain, lowering 
abnormal levels of excitement, and inhibiting the more extreme moods associated with psychotic 
disorders. It is used as acute and maintenance treatment for manic or mixed episodes in bipolar I 
disorder as monotherapy, or as an adjunct to lithium or valproate. It is also used as an adjunct to 
antidepressants for major depressive disorder. While it is also used to treat autistic disorder, it 
has been associated with irritability. 
 Despite aripiprazole’s preferable profile, it does not come without risks. It should not be 
used by elderly with dementia-related psychosis or those with a history of 
leukopenia/neutropenia. The drug presents an increased risk of death or cerebrovascular events, 
hypotension, aspiration pneumonia, seizures, and diabetes. Also, patients receiving aripiprazole 
need to be monitored for hyperglycemia, dyslipidemia, and weight gain. There is also an 
increased risk of suicidal thoughts and behavior in children, adolescents, and young adults. Other 
adverse reactions include drowsiness, headache, anxiety, insomnia, constipation, nausea, 
vomiting, somnolence, fatigue, sedation, dizziness, restlessness, akathisia, blurred vision, tremor, 
pyrexia, salivary hypersecretion, EPS, neuroleptic malignant syndrome, and tardive dyskinesia. 
One challenge in antipsychotic research is that schizophrenia cannot be fully mimicked in 
healthy volunteers or laboratory animals. As such, psychotomimetics (drugs that can mimic some 
symptoms) are used to test the efficacy of antipsychotic drugs to prevent the psychotomimetic 
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drugs’ effects. Amphetamine enhances the release of monoamines, thus increasing the levels of 
dopamine in meso-limbico-cortical and meso-striatal pathways, and may cause delusions and 
hallucinations in humans, mimicking positive symptoms of schizophrenia (Leite et al., 2008). 
Phencyclide, ketamine, and MK-801 act as antagonists at the glutamate NMDA receptor, 
mimicking some positive and negative symptoms such as social isolation and cognitive deficits 
(Leite et al., 2008). Recall that the glutamate hypothesis states that schizophrenia is the result of 
hypo-activity on NMDA receptors, thus explaining why these particular psychomimetics may be 
useful (Leite et al., 2008). In rodents, psychotomimetics induce behavioral changes such as 
motor hyperactivity, reduced social interaction, and impairment in the pre-pulse inhibition of the 
startle reflex (Leite et al., 2008). Aripiprazole has been shown to inhibit the stereotyped behavior 
and the impaired pre-pulse inhibition induced by apomorphine (dopamine agonist) in rats (Leite 
et al., 2008). While aripiprazole did not inhibit spontaneous locomotion, significantly less 
movement was observed (Leite et al., 2008). The drug inhibited amphetamine-induced 
locomotion and cocaine-induced motor hyperactivity, both drugs that enhance dopamine-
mediated neurotransmission. Also, the highest dose of aripiprazole inhibited hyperlocomotion 
induced by MK-801 while the lowest dose of aripiprazole enhanced it. This study also showed 
that the highest dose of aripiprazole produced catalepsy, but to a lower extent than haloperidol 
(Leite et al., 2008). Antipsychotics’ liability to induce catalepsy correlates well with D2 receptor 
antagonism, whereas aripiprazole has been shown to not induce significant motor impairments, 
even in doses that induce 95% of receptor occupation. This is most likely due to its partial 
agonism at these receptors (Leite et al., 2008). Additionally, aripiprazole induces less EPS at 
higher doses than other antipsychotics, demonstrating its lack of aversive side effects (Leite et 
al., 2008). 
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Since previously mentioned studies show that working memory and retention are 
unstable in schizophrenic patients, it would be beneficial to know whether or not Abilify affects 
memory in normal mice, let alone schizophrenic animal models. Schizophrenic patients show 
deficits in spatial WM tasks by having significantly lower recognition rates for previously seen 
objects. They differ from “normal controls in regional cerebral blood flow changes in the 
pulvinar region of the right thalamus and the right or left prefrontal cortex during the recognition 
of new and previously seen objects” (Rajagopal et al., 2014). The hippocampus, the prefrontal 
cortex, the nucleus accumbens, and the dorsal striatum are implicated in the pathobiology of 
schizophrenia (Rajagopal et al., 2014). These neural systems require “closely modulated 
glutamatergic, GABAergic, cholinergic, dopaminergic, serotonergic, and nitric oxide-dependent 
neurotransmitters and growth factors for their action to achieve one-trial memory formation and 
retention for a limited period of time” (Rajagopal et al., 2014, p. 3).  
 The hypotheses of this thesis are that Abilify will significantly increase memory, that the 
lowest dose will induce stereotypy while the highest dose will inhibit stereotypy, and that the 
highest dose will inhibit coordination while the other doses will have little or no effect. 
Methods 
Subjects 
Fifteen adult male (42-58g) and 15 adult female CD-1 mice (33-44g) were purchased 
from Charles River Laboratories Inc., (Portage MI) and housed in the Long Island University 
Animal Vivarium. Animals were housed in same sex groups (8-10 adult mice per cage) in a 
temperature-controlled room maintained on a 12-h light /12-h dark cycle, and food and water 
were available to the mice ad libitum. Mice were divided into 2 groups for both genders, (n = 
10/experimental group and n=5/control group). Control group subjects were tested once while 
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experimental group subjects were tested at three doses, and studies were carried out in 
accordance with The National Institutes of Health Guidelines and regulations specified by the 
LIU-Post Animal Care & Use Committee.   
Drug 
  Abilify (Aripiprazole) was purchased from Fisher Scientific (Union City, CA) and was 
dissolved in 0.9% saline and Tween 80. The drug was tested during their peak time of effect 
(Abilify’s peak time of effect is 30 minutes). A vehicle of 0.9% saline solution was injected as a 
control in 5 males and 5 female mice and used as vehicle comparisons. All intraperitoneal 
injections were administered via 1 milliliter (ml) syringes with 28 gauge needles infused with 
either saline or the drug solution. 
Apparatus 
The Cognitive Maze (see Appendix A) consists of a 30cm x 30cm wooden box with a 
removable Plexiglas top. Spatial memory was tested within this box using a stopwatch 
(Sportline) and an error counter (Sportline) (a picture of the maze and the other lab machinery 
used in the study can be seen in the appendix). 
The Rota-Rod series 8 model (see Appendix B) from the IITC-755 Life Sciences 
Company (Victory Blvd, Woodland Hills, CA 91367) consists of five elevated rods (diameter 
1.25” each, which is optimal for mice to grip onto and run on), and 5 individual lanes enclosed 
via Plexiglas screens. Clear Plexi-Glass front panels are supplied for viewing during test. Test 
parameters are entered via the front panel keyboard. All test results are displayed on the front 
panel display and also sent out the rear panel printer port. The test ending results for each 
position are rpm’s (revolutions per minute), test time, and distance traveled in meters. The user 
selects from 1 to 5 lanes at a time of testing to be included in the test. The Roto-Rod is designed 
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to enable the operator a more precise reading of equilibrium thresholds for coordination and 
endurance. This digitally controlled unit has a high degree of repeatability but all mice are 
acclimated on the machine prior to any baselines or testing. Specifically, mice are placed on 
textured drums to avoid slipping. Textured drums, which act like round-treadmills begin to turn 
slowly and the animal begins to walk on it. When the animal drops off of the textured drum (18.5 
cm), it activates a sensing platform below. Elapsed time, distance, and rpm’s can then be 
recorded.  
             The Coulbourn Tru-Scan Activity Box (see Appendix C) consists of two plexiglas, box-
like arenas containing photobeam sensors (2mm part) along the ventral surface of the arena 
(E63-12 model). Specifically, the Activity Boxes can be used to measure and record various 
horizontal floor movements, stereotypical motions, locomotor activities, as well as other 
behaviors such as jumping and resting through floor and wall sensors. Sensor rings: Tru-Scan’s 
photobeam sensor rings are separate from the station’s processor. There is only one type of 
sensor ring. It senses in two dimensions. The same ring is used for FP (floor plane) sensing. The 
connector into which you plug the ring determines its recording function. The system logs 
coordinates instead of just a “yes or no.” Tru-Scan’s precision is 32 x 32cm, twice the cage’s 
beam resolution; 0.5 inch (1.27 cm) for the beam spacing of the large cage and 0.3 inch (.76 cm) 
for spacing of the small cage. This is accomplished by calculating the spread between the lowest 
and the highest beam blocked and defining the coordinate as one half the distance between the 
two. To get readings, mice need to be placed on the gray, square plastic floor of the activity box 
arena which allows the experimenter to view the mice during the tests. The protocol set up for 
the activity boxes for each mouse was 10 minutes long.  The following operational definitions 
were used for the activity variables.  Total movements (TM) were defined for each movement as 
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a series of successive coordinate changes with no rest for at least 1 sample interval. Latency to 
First Movement (LFM) is defined as datum measuring the latency from run start to the first 
coordinate change and then to the 5th, 10th, 20th, 50th, and 100th unit (inches or centimeters) of 
distance traveled. Rest Time (RT) is operationally defined as the total session time less Total 
Movement Time (TMT) is defined as the sum total of elapsed time of all movements in the floor 
plane). Stereotypy (STPY) or stereotypical movements are measured as repetitive behaviors 
which do not contribute to large location changes progressively further from the starting point 
(e.g., grooming behavior, shaking, or a seizure etc.). Stereotypy Moves are defined as the total 
number of coordinate changes less than plus or minus 0.999 beam spaces in each floor plane (X 
and Y) dimension and back to the original point that do not exceed 2 seconds apart. Stereotypy 
Episodes are defined as the total number of episodes of stereotypic moves. Three such 
movements must be made before a stereotypy episode starts, and when it does, the qualifying 3 
movements are included in the total number of moves. When the subject moves outside of the 
region of qualified coordinates, or fails to move within them for 2 seconds, the episode breaks 
and its current position becomes the new starting point. 
Measurements of body weights were taken on a scale from Salter Housewares 
(Tonbridge, Kent) prior to and after the behavioral testing. 
Procedure 
The study was conducted in a scientific laboratory at a college campus.  Baselines were 
taken on all apparati for all mice prior to the start of the study. Two mice at a time were injected 
with the desired dose (0.1mg/kg, 5mg/kg, 20mg/kg) with an injection volume of 0.2cc’s. 
Twenty-seven minutes after the mice received their dose (which was the peak time of the drug’s 
action), the mice were evaluated (2x each) for distance traveled (how long the mice ran before 
CHARACTERIZING THE BEHAVIORAL EFFECTS OF ARIPIPRAZOLE 18 
 
they fell off the rod), rotations per minute (rpm), and time were recorded both times on the Roto-
Rod. Immediately thereafter, each mouse was separately run through a maze that contained a 
food pellet at the end (this was recorded as elapsed time-to-goal). Time was recorded as the 
amount of seconds it took for a mouse to go from the start of the maze to the food pellets with 3 
minutes as the cut-off time. Maze errors and elapsed time were recorded using a stopwatch and 
an error counter.  An error was recorded every time a mouse went in a direction that did not lead 
to the pellets. The mice were then put in the Tru Scan Activity Arenas and activity was recorded. 
Overall activity was recorded using the Tru Scan for 10 minutes. 10 minutes ensured that the 
mice would be in the activity box during the peak time effect of the antipsychotic medication. 
Data Analysis   
Statistical significance (p < .05) was assessed for analgesia using GraphPad Prism 
Graphing and Statistical program using Student's t test when comparing 2 means or a 1-way 
Analysis of Variance (ANOVA) was used for the comparison of 3 or more means. This was 
followed by Tukey's Post-hoc Test to identify where (which gps) significance was located (San 
Diego, CA, USA). 
Results 
 One-way ANOVA tests were conducted to test for significant effects. If significant 
effects were found, post-hoc comparison’s using Tukey’s post-hoc tests were done. 
 In a dose-dependent manner, Abilify (0.1 – 20 mg/kg) significantly increased latency-to-
goal for female mice (n = 6-10) when challenged in a classic maze, F(2, 22) = 5.50, p < 0.05 (see 
Figure 1b). Tukey’s post-hoc test showed that female mice spent significantly longer time to 
complete the maze at 20mg/kg compared to 0.1mg/kg and 5mg/kg. Abilify (0.1 – 20 mg/kg) did 
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not significantly affect latency to goals for male mice (n = 6-10) when challenged in a classic 
maze, F(2, 22) = 0.77, p > 0.05 (see Figure 1a). 
Abilify (0.1 – 20 mg/kg) did not significantly affect errors in memory for male mice (n = 
6-10) when challenged in a classic maze, F(2, 22) = 0.75, p > 0.05 (see Figure 2a). Abilify (0.1 – 
20 mg/kg) did not significantly affect errors in memory when female mice (n = 6-10) were 
challenged in a classic maze, F(2, 22) = 0.58, p > 0.05 (see Figure 2b).  
Catalepsy is a condition characterized by lack of response to external stimuli and by 
muscle rigidity, so that the limbs remain where they are positioned. Catalepsy is a symptom of 
certain nervous disorders such as Parkinson’s disease and epilepsy, but is also a characteristic 
feature of catatonic schizophrenia. The mice in this study were all examined prior to testing for 
any signs of catalepsy, and no signs were found. Once drug administration was initiated, if any 
signs of catalepsy were seen, it was assumed that this was a result of the drug, not any prior CNS 
dysfunction in the mice. At 20mg, some female mice were cataleptic, eliciting less movement as 
shown by a decrease from the lowest dose. Abilify (0.1 – 20 mg/kg) did not significantly affect 
the total distance that male mice (n = 6-10) traveled on the Rota-Rod, F(3, 110) = 1.24, p > 0.05 
(see Figure 3a). However, in a dose-dependent manner, Abilify (0.1 – 20 mg/kg) significantly 
affected the total distance that female mice (n = 6-10) traveled on the Rota-Rod, F(3, 104) = 
8.83, p < 0.001 (see Figure 3b). Tukey’s post-hoc test verified that all three doses significantly 
impacted total distance traveled in females, as compared to their baseline times. 
Abilify (0.1 – 20 mg/kg) did not significantly affect the total time that male mice (n = 6-
10) spent on the Rota-Rod, F(3, 66) = 0.44, p > 0.05 (see Figure 4a). In a dose-dependent 
manner, Abilify (0.1 – 20 mg/kg) significantly affected the total time that female mice (n = 6-10) 
spent on the Rota-Rod, F(3, 64) = 13.27, p < 0.001 (see Figure 4b). Tukey’s post-hoc test 
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verified that all three doses significantly impacted total time spent on the Rota-Rod in females, as 
compared to their baseline times. 
As dose increased, male mice’s (n = 6-10) coordination was significantly inhibited, 
showing less moves at 20mg dose, F(3, 31) = 11.90, p < 0.001 (see Figure 5a). Tukey’s post-hoc 
test showed the 20mg dose to inhibit coordination significantly compared to the 0.1mg/kg dose, 
the 5mg/kg dose, and baseline. As dose increased, female mice’s (n = 6-10) coordination was 
significantly inhibited, showing less moves at 20mg dose, F(3, 32) = 27.54, p < 0.001 (see 
Figure 5b). Tukey’s post-hoc test showed the 20mg dose to inhibit coordination significantly 
compared to the 0.1mg/kg dose, the 5mg/kg dose, and baseline. 
As dose increased, male mice’s (n = 6-10) rest time significantly increased, F(3, 31) = 
34.29, p < 0.001 (see Figure 6a). Tukey’s post-hoc test showed the 20mg/kg dose to significantly 
increase rest time compared to the other doses and baseline, and the 5mg/kg dose significantly 
increased rest time compared to baseline. As dose increased, female mice’s (n = 6-10) rest time 
significantly increased, F(3, 32) = 68.67, p < 0.001 (see Figure 6b). Tukey’s post-hoc test 
showed all doses to be significant compared to each other and to baseline. 
As dose increased, male mice’s (n = 6-10) stereotypic movements significantly 
decreased, F(3, 31) = 9.75, p < 0.001 (see Figure 7a). Tukey’s post-hoc test showed the 20mg/kg 
dose to cause less stereotypy moves compared to the other doses, and 0.1mg/kg to cause 
significantly more stereotypic movements compared to baseline. As dose decreased, female 
mice’s (n = 6-10) stereotypic movements significantly increased, F(3, 32) = 14.17, p < 0.001 
(see Figure 7b). Tukey’s post-hoc test showed the 0.1mg/kg to cause significantly more 
stereotypic movements compared to the 5mg/kg dose, the 20mg/kg dose, and baseline. 
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In a dose-dependent manner, Abilify significantly impacted the number of stereotypic 
episodes in male mice (n = 6-10), F(3, 31) = 10.16, p < 0.001 (see Figure 8a). Tukey’s post-hoc 
test showed that the 0.1mg/kg significantly increased stereotypy episodes compared to baseline, 
and that the 20mg/kg dose significantly reduced stereotypy episodes compared to the other 
doses. In a dose-dependent manner, Abilify significantly impacted the number of stereotypic 
episodes in female mice (n = 6-10), F(3, 32) = 19.90, p < 0.001 (see Figure 8b). Tukey’s post-
hoc test showed that the 0.1mg/kg significantly increased stereotypy episodes compared to the 
other doses and baseline, and that the 20mg/kg dose significantly reduced stereotypy episodes 
compared to the other doses and baseline. 
In a dose-dependent manner, Abilify significantly impacted time spent engaging in 
stereotypy in male mice (n = 6-10), F(3, 31) = 9.24, p < 0.001 (see Figure 9a). Tukey’s post-hoc 
test showed the 0.1mg/kg dose to significantly increase stereotypy time compared to baseline, 
and the 20mg/kg dose to significantly decrease stereotypy time compared to the other doses. As 
dose decreased, time spent engaging in stereotypy significantly increased in female mice (n = 6-
10), F(3, 32) = 9.20, p < 0.001 (see Figure 9b). Tukey’s post-hoc test showed the 0.1mg/kg dose 
to significantly increase stereotypy time compared to the other doses and baseline. 
Discussion 
 Our hypothesis that Abilify would improve memory was not supported by our results. 
The cognitive enhancement of atypical antipsychotics is attributed to antagonist activity at 5-HT6 
and 5-HT7 receptors, and since aripiprazole works as an antagonist at 5-HT7 receptors, we 
expected to see Abilify enhance cognition in our study. However, neither the males nor the 
females showed cognitive improvement. The male mice committed the most errors at the 
20mg/kg dose, the second most at the 0.1mg/kg dose, and the fewest at the 5mg/kg dose, while 
CHARACTERIZING THE BEHAVIORAL EFFECTS OF ARIPIPRAZOLE 22 
 
the exact opposite pattern was true for the female mice. Such contradictory results are difficult to 
interpret. While both males and females spent more time in the maze at the highest dose, the 
effect was significant only for the females, which might have something to do with the 
involvement of prolactin in the females. Our findings regarding coordination showed that the 
female mice’s coordination was more inhibited compared to the male mice, meaning that the 
female mice perhaps took longer in the maze at the highest dose due to greater inhibited 
coordination than the males, rather than any cognitive differences. While the results conflicted 
with our hypothesis, we could see gender differences at doses showing that most errors were 
committed by excessive time spent in maze. Again, this memory problem could be due to a 
prolactin change in females that was not seen in males. 
 We hypothesized that the highest dose would inhibit coordination, which was mostly 
supported by our findings. While the results were not significant for the male mice, all doses 
produced shorter distances traveled in the Rota-Rod compared to baseline for the female mice. 
Remarkably, even the lowest dose had a stronger impact on female mice than any of the doses 
had on the male mice. Also, the lowest and highest dose produced less distance travelled than the 
middle dose. The time spent by male mice on the Rota-Rod was not significant depending on 
dose, and the results were quite consistent across the doses and baseline. All doses significantly 
reduced time on the Rota-Rod compared to baselines for the female mice. The female mice 
seemed to experience inhibited coordination at all doses, whereas the males experienced no 
significant inhibition. Also, the middle dose was closest to the baselines for the females, once 
again. The highest dose caused significantly fewer moves and thus showed inhibited 
coordination among the male mice. The lowest and middle dose produced more moves than 
baseline, without being significant. The highest dose caused significantly fewer moves in the 
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female mice as well, indicating inhibited coordination. In males, the highest dose produced 
significant effects across all conditions, while the middle dose also produced significantly more 
rest time compared to baseline. All doses significantly increased rest time compared to baseline 
in female mice, and the rest time also increased significantly in a dose-dependent manner. 
 We hypothesized that the lowest dose would increase stereotypy and that the highest dose 
would inhibit stereotypy, which was generally supported by our findings. In male mice, the 
highest dose produced significantly fewer stereotypic moves compared to the other doses, and 
the lowest dose produced significantly more moves compared to baseline. In females, the lowest 
dose produced significantly more stereotypic moves compared to the other doses and baseline, 
while the highest dose produced less stereotypic moves in a non-significant manner, and the 
middle dose was comparable to baseline. In male mice, the lowest dose produced significantly 
more stereotypic episodes compared to the highest dose and baseline, and the highest dose 
produced significantly more episodes compared to the middle dose. In females, the lowest dose 
produced significantly more episodes compared to the other doses and baseline, and the highest 
dose produced significantly fewer episodes compared to the other doses and baseline. In male 
mice, there was a significant difference in stereotypy time between the highest and the lowest 
dose, while the lowest dose produced significantly longer time than baseline, and the highest 
dose produced significantly less time than the middle dose. In female mice, the lowest dose 
produced significantly more stereotypy time compared to the other doses and baseline. 
 At moderate to high doses of Abilify, catalepsy or a modified form of catalepsy may arise 
when individulas sustain their limbs in the same position for very long periods of time, which 
may lead to significant health problems, such as formation of the blood clots. Also, since high 
doses of Abilify is linked to slowing down of bodily functions a possible future study should 
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include evaluating respiratory depression. Also, we did note gender differences among the male 
and female mice, and these differences could be investigated by future studies. 
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Figure 1a. Latency-to-goal in seconds for male mice in a cognitive maze at 0.1mg/kg, 5 mg/kg, 
and 20mg/kg doses of Abilify. 
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Figure 1b. Latency-to-goal in seconds for female mice in a cognitive maze at 0.1mg/kg, 5 
mg/kg, and 20mg/kg doses of Abilify. 
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Figure 2a. Number of errors made by male mice in a cognitive maze at 0.1mg/kg, 5 mg/kg, and 
20mg/kg doses of Abilify. 
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Figure 2b. Number of errors made by female mice in a cognitive maze at 0.1mg/kg, 5 mg/kg, 
and 20mg/kg doses of Abilify. 
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Figure 3a. Distance traveled in cm by male mice on the Rota-Rod at 0.1mg/kg, 5 mg/kg, and 
20mg/kg doses of Abilify. 
CHARACTERIZING THE BEHAVIORAL EFFECTS OF ARIPIPRAZOLE 33 
 
Rotorod Distance Females
0.
1 5 20
0
20
40
60
Baseline Average
Figure 3b
Abilify Dose (mg)
D
is
ta
n
c
e
 T
ra
v
e
le
d
 (
c
m
)
 
Figure 3b. Distance traveled in cm by female mice on the Rota-Rod at 0.1mg/kg, 5 mg/kg, and 
20mg/kg doses of Abilify. 
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Figure 4a. Time in seconds spent by male mice on the Rota-Rod at 0.1mg/kg, 5 mg/kg, and 
20mg/kg doses of Abilify. 
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Figure 4b. Time in seconds spent by female mice on the Rota-Rod at 0.1mg/kg, 5 mg/kg, and 
20mg/kg doses of Abilify. 
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Figure 5a. Number of fixed moves made by male mice in the Tru-Scan at 0.1mg/kg, 5 mg/kg, 
and 20mg/kg doses of Abilify. 
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Figure 5b. Number of fixed moves made by female mice in the Tru-Scan at 0.1mg/kg, 5 mg/kg, 
and 20mg/kg doses of Abilify. 
CHARACTERIZING THE BEHAVIORAL EFFECTS OF ARIPIPRAZOLE 38 
 
Fixed Rest Time Males
0.
1 5 20
0
200
400
600
Baseline Average
Figure 6a
Abilify Dose (mg)
R
e
s
t 
T
im
e
 (
s
e
c
)
 
Figure 6a. Rest time in seconds spent by male mice in the Tru-Scan at 0.1mg/kg, 5 mg/kg, and 
20mg/kg doses of Abilify. 
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Figure 6b. Rest time in seconds spent by female mice in the Tru-Scan at 0.1mg/kg, 5 mg/kg, and 
20mg/kg doses of Abilify. 
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Figure 7a. Number of stereotypic moves made by male mice in the Tru-Scan at 0.1mg/kg, 5 
mg/kg, and 20mg/kg doses of Abilify. 
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Figure 7b. Number of stereotypic moves made by female mice in the Tru-Scan at 0.1mg/kg, 5 
mg/kg, and 20mg/kg doses of Abilify. 
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Figure 8a. Number of stereotypic episodes made by male mice in the Tru-Scan at 0.1mg/kg, 5 
mg/kg, and 20mg/kg doses of Abilify. 
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Figure 8b. Number of stereotypic episodes made by female mice in the Tru-Scan at 0.1mg/kg, 5 
mg/kg, and 20mg/kg doses of Abilify. 
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Figure 9a. Time in seconds spent by male mice making stereotypic movements in the Tru-Scan 
at 0.1mg/kg, 5 mg/kg, and 20mg/kg doses of Abilify. 
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Figure 9b. Time in seconds spent by female mice making stereotypic movements in the Tru-
Scan at 0.1mg/kg, 5 mg/kg, and 20mg/kg doses of Abilify. 
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Table 1. Statistical analysis of Abilify’s effect on coordination in males. 
Parameter           
Table Analyzed Rotorod Time Males         
            
One-way analysis of variance           
P value 0.7192         
P value summary ns         
Are means signif. different? (P < 0.05) No         
Number of groups 4         
F 0.4484         
R squared 0.01998         
            
Bartlett's test for equal variances           
Bartlett's statistic (corrected) 3.134         
P value 0.3715         
P value summary ns         
Do the variances differ signif. (P < 0.05) No         
            
ANOVA Table SS df MS     
Treatment (between columns) 36.44 3 12.15     
Residual (within columns) 1788 66 27.09     
Total 1824 69       
            
Tukey's Multiple Comparison Test Mean Diff. q Significant? P < 0.05? Summary 95% CI of diff 
0.1 vs 5 1.850 1.590 No ns -2.493 to 6.193 
0.1 vs 20 0.4500 0.3157 No ns -4.869 to 5.769 
0.1 vs Baseline 1.000 0.8592 No ns -3.343 to 5.343 
5 vs 20 -1.400 0.9822 No ns -6.719 to 3.919 
5 vs Baseline -0.8500 0.7304 No ns -5.193 to 3.493 
20 vs Baseline 0.5500 0.3859 No ns -4.769 to 5.869 
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Table 2. Statistical analysis of Abilify’s effect on coordination in females. 
Parameter           
Table Analyzed 
Rotorod Time 
Females         
            
One-way analysis of variance           
P value < 0.0001         
P value summary ***         
Are means signif. different? (P < 0.05) Yes         
Number of groups 4         
F 13.27         
R squared 0.3835         
            
Bartlett's test for equal variances           
Bartlett's statistic (corrected) 18.69         
P value 0.0003         
P value summary ***         
Do the variances differ signif. (P < 0.05) Yes         
            
ANOVA Table SS df MS     
Treatment (between columns) 3175 3 1058     
Residual (within columns) 5105 64 79.76     
Total 8280 67       
            
Tukey's Multiple Comparison Test Mean Diff. q Significant? P < 0.05? Summary 95% CI of diff 
0.1 vs 5 -0.6500 0.3255 No ns -8.106 to 6.806 
0.1 vs 20 6.300 2.385 No ns -3.563 to 16.16 
0.1 vs Baseline -13.50 6.760 Yes *** -20.96 to -6.044 
5 vs 20 6.950 2.631 No ns -2.913 to 16.81 
5 vs Baseline -12.85 6.435 Yes *** -20.31 to -5.394 
20 vs Baseline -19.80 7.495 Yes *** -29.66 to -9.937 
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Table 3. Statistical analysis of Abilify’s effect on endurance in males. 
Parameter           
Table Analyzed 
Rotorod Distance 
Males         
            
One-way analysis of variance           
P value 0.2994         
P value summary ns         
Are means signif. different? (P < 0.05) No         
Number of groups 4         
F 1.238         
R squared 0.03266         
            
Bartlett's test for equal variances           
Bartlett's statistic (corrected) 39.10         
P value < 0.0001         
P value summary ***         
Do the variances differ signif. (P < 0.05) Yes         
            
ANOVA Table SS df MS     
Treatment (between columns) 4260 3 1420     
Residual (within columns) 126200 110 1147     
Total 130400 113       
            
Tukey's Multiple Comparison Test Mean Diff. q Significant? P < 0.05? Summary 95% CI of diff 
0.1 vs 5 6.400 0.8451 No ns -21.57 to 34.37 
0.1 vs 20 2.000 0.2156 No ns -32.26 to 36.26 
0.1 vs Baseline -8.734 1.424 No ns -31.39 to 13.92 
5 vs 20 -4.400 0.4744 No ns -38.66 to 29.86 
5 vs Baseline -15.13 2.467 No ns -37.79 to 7.525 
20 vs Baseline -10.73 1.318 No ns -40.81 to 19.34 
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Table 4. Statistical analysis of Abilify’s effect on endurance in females. 
Parameter           
Table Analyzed 
Rotorod Distance 
Females         
            
One-way analysis of variance           
P value < 0.0001         
P value summary ***         
Are means signif. different? (P < 0.05) Yes         
Number of groups 4         
F 8.831         
R squared 0.2030         
            
Bartlett's test for equal variances           
Bartlett's statistic (corrected) 48.65         
P value < 0.0001         
P value summary ***         
Do the variances differ signif. (P < 0.05) Yes         
            
ANOVA Table SS df MS     
Treatment (between columns) 49540 3 16510     
Residual (within columns) 194500 104 1870     
Total 244000 107       
            
Tukey's Multiple Comparison Test Mean Diff. q Significant? P < 0.05? Summary 95% CI of diff 
0.1 vs 5 -2.950 0.3051 No ns -38.72 to 32.82 
0.1 vs 20 13.13 1.026 No ns -34.19 to 60.44 
0.1 vs Baseline Females -41.48 5.254 Yes ** -70.69 to -12.28 
5 vs 20 16.08 1.257 No ns -31.24 to 63.39 
5 vs Baseline Females -38.53 4.881 Yes ** -67.74 to -9.330 
20 vs Baseline Females -54.61 4.745 Yes ** -97.18 to -12.04 
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Appendix A 
Cognitive Maze 
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Appendix B 
Rota-Rod series 8 model 
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Appendix C 
The Coulbourn Tru-Scan Activity Box 
 
 
